To investigate the efficacy of etanercept and @entity1500 ( @entity1499 ) combination therapy in Chinese @entity1 with @entity1691 @entity2720 , the possible courses and maintenance protocol, altogether 97 @entity1691 @entity1 fulfilling the modified New York criteria with @entity2720 were enrolled in a 12-month trial treated with combined etanercept and @entity1500 . All these @entity1 were required to be poor responders to SSZ ( @entity3378 ) or @entity1500 therapy for 6 consecutive months or the longer. Etanercept was administered subcutaneously twice a week at a fixed dosage of 25 mg for the first six months, followed by 25 mg once a week in @entity1 with good control of both symptoms and radiological progression, or twice a week for another six months in @entity1 with BASDAI > or = 4. Combined @entity1500 was administered intravenously once a week at the dosage of 15 mg. Demographics, clinical and laboratory features, physical function and quality of life using the Bath @entity1691 Activity Index (BASDAI), the Bath @entity1691 Functional Index (BASFI), Harris hip score, and radiological assessment using the BASRI-hip index were recorded. Most @entity1 achieved @entity158 release at the end point of assessment. Significant improvement in Bath @entity5427 Activity Index (BASDAI) (P < 0.05), Bath AS Functional Activity Index (BASFI) (P < 0.05), and Harris hip score (P < 0.05) was demonstrated. Radiographic progression was recorded as no exacerbation or alleviated. Larger interval between two etanercept administrations would provide similar advantages to standard method and possibly less adverse events if @entity1500 was combined. Etanercept and @entity1500 combination therapy was beneficial to @entity1691 @entity1 with @entity2720 , and staged dosage deduction in the long term proved to be effective as well as adverse event preventing.

Treatment efficacy of etanercept and @entity1500 combination therapy for @entity1691 XXXX in Chinese population.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity5427 :: ('MESH:D017204', 'Disease') :: ['AS Disease'] @entity1691 :: ('MESH:D013167', 'Disease') :: ['Ankylosing Spondylitis Disease', 'ankylosing spondylitis', 'Ankylosing Spondylitis'] @entity1500 :: ('CHEBI:44185', 'Chemical') :: ['MTX'] @entity158 :: ('MESH:D010146', 'Disease') :: ['pain'] @entity2720 :: ('MESH:D007592', 'Disease') :: ['hip joint lesion'] @entity1499 :: ('MESH:D008727', 'Chemical') :: ['methotrexate'] @entity3378 :: ('MESH:D012460', 'Chemical') :: ['Sulfasalazine']
@entity2720 :: (MESH:D007592,Disease) :: ['hip joint lesion']
